Related Experiment Video
Updated: Dec 23, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
The Associations between Liver Enzymes and Cardiovascular Risk Factors in Adults with Mild Dyslipidemia
Eun-Ock Park1, Eun Ju Bae2, Byung-Hyun Park3
1Clinical Trial Center for Functional Foods, Chonbuk National University Hospital, Jeonju 54907, Jeonbuk, Korea.
Insights
Elevated liver enzymes like gamma-glutamyltransferase (GGT) are linked to increased cardiovascular disease (CVD) risk in individuals with mild dyslipidemia. Routine GGT screening can aid early CVD detection in these patients.
Area of Science:
- Cardiology
- Hepatology
- Clinical Biochemistry
Background:
- Hypertension and dyslipidemia are significant cardiovascular disease (CVD) risk factors.
- Abnormal liver function tests may indicate heightened CVD risk, even with mild dyslipidemia.
Purpose of the Study:
- To investigate the relationship between liver enzymes and cardiovascular risk factors in patients with mild dyslipidemia.
- To determine if liver enzymes can predict cardiovascular risk in this population.
Main Methods:
- Analysis of 438 participants from nine clinical studies (2009-2019) at Chonbuk National University Hospital.
- Assessment of trends in blood pressure and cardiovascular risk factors across quartiles of serum liver enzymes (GGT, ALT, AST, ALP).
- Multivariate logistic regression analysis to determine odds ratios for hypertension adjusted for lifestyle factors.
Main Results:
- Significant linear increases in blood pressure and cardiovascular risk factors were observed with rising GGT and ALT levels.
- Hypertension prevalence increased across GGT and ALT quartiles.
- Highest GGT quartile showed a 3.688 odds ratio for hypertension, indicating GGT as a strong predictor.
Conclusions:
- Gamma-glutamyltransferase (GGT) is a superior marker for predicting CVD risk among liver enzymes in patients with mild dyslipidemia.
- Routine plasma GGT screening can facilitate early CVD detection in individuals with mild dyslipidemia.
Abstract:
Hypertension and dyslipidemia often occur as comorbidities, with both being strong risk factors for developing cardiovascular diseases (CVD). Abnormal liver function test could reflect a potential CVD risk even in patients with mild dyslipidemia. The aim of this study was to assess the compounding relationship between liver enzymes and cardiovascular risk factors in subjects with mild dyslipidemia. The present analysis was performed among 438 participants who had enrolled in at least one of the nine clinical studies done at the Chonbuk National University Hospital between 2009 and 2019. Significant linear increasing trends were observed in blood pressure level and other cardiovascular risk factors across quartiles of serum γ-glutamyltransferase (GGT) or alanine aminotransferase (ALT), with the increment in hypertension prevalence occurring across the quartiles of GGT and ALT. On multivariate logistic regression analyses, the odds ratios for hypertension, adjusted for smoking, drinking and obesity, in the highest quartiles of GGT, ALT, aspartate aminotransferase, and alkaline phosphatase were 3.688, 1.617, 1.372, and 1.166, respectively. Our study indicates that GGT is a superior marker for predicting CVD risk among liver enzymes. Routine screening of plasma GGT levels in patients with mild dyslipidemia will allow for early detection of CVD.
Related Concept Videos
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management
Lipids: Dietary Sources and Requirements
Cholesterol: Significance and Regulation
Considering cholesterol and...
Atherosclerosis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

